NHLD - National Holdings Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
3.4600
+0.3300 (+10.54%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close3.1300
Open3.2500
Bid3.21 x 1800
Ask3.80 x 900
Day's Range3.2700 - 3.6500
52 Week Range2.5300 - 4.8100
Volume58,297
Avg. Volume33,145
Market Cap43.632M
Beta (3Y Monthly)0.84
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateMay 13, 2019 - May 17, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend Date1996-05-02
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    National Holdings Corporation Reports Financial Results for the Fiscal First Quarter 2019

    NEW YORK, Feb. 15, 2019 -- National Holdings Corporation (NASDAQ: NHLD) (“National” or the “Company”), a leading full service independent brokerage, investment banking, trading.

  • GlobeNewswire4 days ago

    National Holdings Announces Changes to its Board of Directors with Appointments of Two New Independent Directors  

    Michael Mullen, Chairman and Chief Executive Officer of National stated, “We are pleased to welcome Barbara and Jeffrey to our Board of Directors. Each of them brings a unique wealth of knowledge to our board with deep experience in the financial services industry.

  • GlobeNewswire13 days ago

    National Holdings Announces Addition of Arthur R. Hogan to Management Team as Managing Director, Chief Market Strategist

    National Holdings Corporation (NHLD) (“National” or the “Company”), a leading full service independent brokerage, investment banking, trading and asset management firm providing diverse services including tax preparation, today announced the addition of Arthur (“Art”) R. Hogan, III to National as Managing Director, Chief Market Strategist. Mr. Hogan joins National with over three decades of financial market experience, primarily focused on the US equity markets. Michael Mullen, Chairman and Chief Executive Officer of National stated, “Art is a capital markets expert of the highest caliber and we are extremely pleased to welcome him to the National team.

  • GlobeNewswire26 days ago

    Aqua Metals Announces Closing of Common Stock Offering and Exercise in Full of Underwriter’s Overallotment Option

    Aqua Metals, Inc. (AQMS), (“Aqua Metals” or the “Company”), which is commercializing its proprietary AquaRefining™ electrochemical lead recycling technology, today announced the closing of its previously announced offering of 5,175,000 shares of common stock at a public offering price of $1.90 per share. Gross proceeds to Aqua Metals from this offering are approximately $10 million before deducting underwriting discounts, commissions and other offering expenses. Aqua Metals intends to use the net proceeds from the offering for working capital, which could include capital expenditures related to addressing operational efficiencies and the expansion of production activities at its initial AquaRefining facility at the Tahoe Regional Industrial Center, McCarran, Nevada, and general corporate purposes.

  • GlobeNewswirelast month

    Aqua Metals Prices Public Offering of Common Stock

    Aqua Metals, Inc. (AQMS), (“Aqua Metals” or the “Company”), which is commercializing its proprietary AquaRefining™ electrochemical lead recycling technology, today announced the pricing of its previously announced underwritten public offering of 4,500,000 common shares at an offering price of $1.90 per share. In addition, Aqua Metals has granted the underwriter a 45-day option to purchase up to an additional 675,000 shares to cover over-allotments, if any. All of the common shares are being offered by the Company.

  • GlobeNewswirelast month

    Aqua Metals Announces Proposed Public Offering of Common Stock

    Aqua Metals, Inc. (AQMS), (“Aqua Metals” or the “Company”), which is commercializing its proprietary AquaRefining™ electrochemical lead recycling technology, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Aqua Metals expects to grant the underwriter a 45-day option to purchase up to an additional 15 percent of the shares of common stock offered in the public offering to cover over-allotments, if any. All of the common shares are being offered by the Company.

  • GlobeNewswire2 months ago

    National Holdings Corporation Reports Record Financial Results for the 2018 Fiscal Year

    NEW YORK, Dec. 21, 2018 -- National Holdings Corporation (NASDAQ: NHLD) (“National” or the “Company”), a leading full service independent brokerage, investment banking, trading.

  • GlobeNewswire2 months ago

    Eyenovia Prices Public Offering of Common Stock

    Eyenovia, Inc. (“Eyenovia” or the “Company”) (EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print technology, has priced its underwritten public offering of 1,200,000 shares of common stock at an offering price of $2.45 per share. All of the shares are being offered by the Company. The Company expects to receive gross proceeds from the offering, excluding the exercise of the over-allotment option, if any, of approximately $2.9 million, excluding underwriting discounts and commissions and other offering-related expenses.

  • PR Newswire6 months ago

    Workhorse Group Announces Proposed Public Offering of its Common Stock

    CINCINNATI, Aug. 8, 2018 /PRNewswire/ -- Workhorse Group Inc. (NASDAQ: WKHS) ("Workhorse" or "the Company"), an American technology company focused on providing sustainable and cost-effective electric mobility solutions to the transportation sector, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. Workhorse expects to grant the underwriter a 45-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering to cover over-allotments, if any.

  • Reuters7 months ago

    Special Report: Biotech incubator taps investors through in-house brokerage

    Last August, National Securities Corp analyst Jonathan Aschoff was bullish on Avenue Therapeutics Inc (ATXI.O), a fledgling biotechnology company with no revenue and one drug in clinical trials. Nearly a year later, Avenue shares are down 36 percent, at about $4. A few months earlier, Aschoff had waxed equally optimistic about another biotech venture, Checkpoint Therapeutics Inc (CKPT.O), with several cancer drugs in various stages of development.